<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="913">
  <stage>Registered</stage>
  <submitdate>28/11/2005</submitdate>
  <approvaldate>7/12/2005</approvaldate>
  <actrnumber>ACTRN12605000778684</actrnumber>
  <trial_identification>
    <studytitle>The treatment of stable obesity hypoventilation syndrome (OHS)</studytitle>
    <scientifictitle>A randomised controlled trial of the effects of one night of CPAP (Continuous Positive Airway Pressure), Bilevel(s, spontaneous mode) or Bilevel(c, controlled mode) therapy on sleep and oxygenation in the Obesity Hypoventilation Syndrome (OHS)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity hypoventilation syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The effects of one night of CPAP, Bilevel (s) and Bilevel (c) for OHS. Each subject will be studied on all 3 therpay modes (crossover trial, with 2 week washout period in between)</interventions>
    <comparator>CPAP, Bilevel (s) and Bilevel (c) for OHS as above. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Arousals from sleep per hour</outcome>
      <timepoint>Raw Polysomnographic (sleep study) data are collected during each overnight sleep study and summary indices are generated later.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Rate of desaturation</outcome>
      <timepoint>Raw Polysomnographic (sleep study) data are collected during each overnight sleep study and summary indices are generated later.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Sleepiness</outcome>
      <timepoint>Assessed each morning.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Machine preference</outcome>
      <timepoint>At study conclusion.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Clinically stable people with OHS. Stability defined as &gt; 3 months on current therapy (either CPAP, Bilevel(s) or Bilevel(c).Obesity (Body Mass Index &gt; 30 kg/m2)Hypoventilation; Daytime hypercapnia (PaCO2 &gt; 45 mmHg) with or without acidosis prior to initiation of treatment for OHS.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Physician diagnosed Chronic Obstructive Pulmonary Disease (COPD)Respiratory failure attributable to other causes, eg neuromuscular disease. An inability to provide informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed, opaque envelopes</concealment>
    <sequence>Computer generated random sort of the 6 possible combinations of treatment order</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>The same device will deliver all modes of therapy (patient blinding). All summary sleep indices will be generated by a scientist blinded to the treatment type (blinded assesor)</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/01/2006</anticipatedstartdate>
    <actualstartdate>1/05/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/06/2011</actualenddate>
    <samplesize>10</samplesize>
    <actualsamplesize>15</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Austin Health</primarysponsorname>
    <primarysponsoraddress>Studley Rd. Heidelberg 3084
Vic</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Institute for breathing and sleep</fundingname>
      <fundingaddress>Bowen Centre. Austin Health
Studley Rd. Heidelberg 3084
Vic</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Austin Health</sponsorname>
      <sponsoraddress>Studley Rd. Heidelberg 3084
Vic</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will address two important questions. We anticipate that the results of this study will assist us with the clinical management of Victorian Respiratory Support Service patients with Obesity Hypoventilation Syndrome. In addition, we are leading the planning of a multi-centre RCT of non-invasive ventilation treatment in Obesity Hypoventilation Syndrome. Data from the current project will assist with the design of that application (for submission next year to the NHMRC) in terms of sample size estimations, feasibility and the provision of pilot data.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Heath Human Ethics</ethicname>
      <ethicaddress>Studley Rd. Heidelberg 3084
Vic</ethicaddress>
      <ethicapprovaldate>2/06/2006</ethicapprovaldate>
      <hrec> H2006/02430</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>David Berlowitz</name>
      <address>Austin Health
Studley Rd
Heidelberg VIC 3084</address>
      <phone>+61 3 94963871</phone>
      <fax />
      <email>david.berlowitz@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>David Berlowitz</name>
      <address>Austin Health
Studley Rd
Hiedelberg VIC 3084</address>
      <phone>+61 3 49693871</phone>
      <fax />
      <email>david.berlowitz@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Mark Howard</name>
      <address>Austin Health
Studley Rd Heidelberg 3084 Vic</address>
      <phone>+61394963688</phone>
      <fax />
      <email>mark.howard@austin.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>